0001209191-19-048892.txt : 20190909
0001209191-19-048892.hdr.sgml : 20190909
20190909162001
ACCESSION NUMBER: 0001209191-19-048892
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190906
FILED AS OF DATE: 20190909
DATE AS OF CHANGE: 20190909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sheridan John F
CENTRAL INDEX KEY: 0001365369
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36189
FILM NUMBER: 191083247
MAIL ADDRESS:
STREET 1: C/O TANDEM DIABETES CARE, INC.
STREET 2: 11045 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC
CENTRAL INDEX KEY: 0001438133
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 204327508
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11075 ROSELLE STREET
CITY: San Diego
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-366-6900
MAIL ADDRESS:
STREET 1: 11075 ROSELLE STREET
CITY: San Diego
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-06
0
0001438133
TANDEM DIABETES CARE INC
TNDM
0001365369
Sheridan John F
C/O TANDEM DIABETES CARE, INC.,
11075 ROSELLE STREET
SAN DIEGO
CA
92121
0
1
0
0
PRESIDENT & CEO
Common Stock
2019-09-06
4
M
0
9538
2.59
A
12039
D
Common Stock
2019-09-06
4
S
0
9538
70.03
D
2501
D
Stock Option
2.59
2019-09-06
4
M
0
9538
0.00
D
Common Stock
9538
32129
D
Represents shares of common stock received upon exercise of a stock option award.
The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2019.
The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $70.00 to $70.05. The reporting person undertakes to provide the SEC, the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter
The expiration date for these options is ten (10) years from the date of grant.
/s/David B. Berger, Attorney-in-Fact for John F. Sheridan
2019-09-09